Process development, analytical development, analysis, stability testing, manufacturing
Crystal structure by X-ray, solid form screening, solid form selection, IP support
Formulation development, analytical development, manufacturing, stability studies
Packaging, labeling, clinical trial logistics
Mass spectrometry, immunochemistry, flow cytometry, in-vitro drug discovery, clinical trial services
Scientific report writing, module 3 writing, regulatory CMC support
Guiding your nanomedicine candidate through its journey to the clinic
Developing and manufacturing formulations that lead to improved bioavailability
Meeting your needs from pre-clinical to small-scale commercial manufacturing
Bringing your oral drug to clinical trials quickly and reliably
Guiding you through the development of injectable drug products to GMP standards
Enhancing biomolecule purity with tailored solutions for GMP-grade materials at scale
Using the right standards at the right development phase, our comprehensive program management services streamline your small molecule drug development.
Helping you turn your compounds that show promise into GMP-grade drug substances.
We advance your clinical candidates through the pipeline quickly and safely with specialist drug product services.
Our bioanalytical platform supports your preclinical and clinical stages with expert testing services.
Our comprehensive CMC regulatory services streamline preparation and submission of your registration file.
Using the right standards at the right development phase, our comprehensive program management services streamline your large molecule drug development.
We advance your large molecule candidates through the pipeline quickly and safely with specialist drug product services.
Our bioanalytical platform supports your large molecule drugs through preclinical and clinical stages with expert testing services.
Our comprehensive CMC regulatory services streamline the preparation and submission of the regulatory files for your large molecule drug.
Using the right standards at the right development phase, our comprehensive program management services streamline your nanomedicine drug development.
We turn your nanomedicine candidates into suitable drugs with specialist development and manufacturing services.
Our bioanalytical platform supports your preclinical and clinical stages with expert testing services.
Our comprehensive CMC regulatory services streamline the preparation and submission of the regulatory files for your nanomedicines.
Always agile, we reliably guide you and your molecule through the challenging terrain of early phase development
Carefully engineered to support and enable early phase development for our partners’ oral drugs, injectables and nanomedicines
Our leadership team has a deep scientific understanding combined with exceptional experience
Platforms and facilities that are uniquely engineered to support and enable integrated early phase development
We’re a fast-growing EU-based company with many opportunities for you to grow and progress with us
Much more than just smoke – from mar… Resources
The history of cannabis begins already in antiquity and its therapeutic use has been documented for 2700 years. In the year 1850, cannabis was included in the United States Pharmacopoeia (USP) before it was deleted in 1942, after a new legislation in 1937 classified cannabis as a narcotic and was subsequently prohibited. Since that time, the story of cannabis has been told by baby boomer generations as “the mind-expanding, peace-making smoke” that can land you in jail.
But beside the psychotropic effects, many patients and even doctors swore by the effectiveness of cannabinoids in important therapeutic areas like chronic pain, terminal cancer, and multiple sclerosis. Due to the illegal status these applications remained anecdotal until its legalization. Within a short period thereafter scientific interest took off at a rocket speed triggering a flood of clinical studies with parts of the cannabis plant, its resin or extracts investigating different indications. Until today only a few products were approved by regulatory authorities using either synthetic Δ9-tetrahydrocannabinol (THC) (Marinol ®, Syndros®, Cesamed®) or plant derived standardized cannabidiol (CBD) or CBD/THC extracts (Epididex®, Sativex®). Overconfidence in cannabis per se was soon challenged by many failed endpoints in clinical trials. These setbacks led to more basic research on the different cannabis varieties, the active components, their pharmacology and metabolomics, structure-activity relationships, synergistic effects of compounds (entourage effect) and targeted receptors. The more these research progresses the more we understand the complex nature of cannabis as well as the multitude of chemical compounds and structures with the potential of novel therapeutic application.
Please fill out the form to unlock the rest of the content.
Our team members share deep, scientific understanding and insights into their respective fields of expertise.
Sign up to receive drug development insights, the latest on industry trends & Ardena news.